

18. The isolated RANTES of claim 15, wherein the purified RANTES lacks NH₂-terminal amino acids corresponding to amino acid residue 1 of naturally-occurring RANTES (SEQ ID NO. 2).

19. The isolated RANTES of claim 15, wherein the purified RANTES lacks NH₂-terminal amino acids corresponding to amino acid residues 1-3 of naturally-occurring RANTES (SEQ ID NO. 2).

20. The isolated RANTES of claim 15, wherein the purified RANTES lacks NH₂-terminal amino acids corresponding to amino acid residues 1-4 of naturally-occurring RANTES (SEQ ID NO. 2).

21. The isolated RANTES of any one of claims 15 through 20 wherein the truncated RANTES is in glycosylated form.

22. A pharmaceutical composition comprising a truncated RANTES of any one of claims 15 through 20 and one or more pharmaceutically acceptable carriers and/or excipients.

23. A pharmaceutical composition comprising a truncated RANTES of claim 21 and one or more pharmaceutically acceptable carriers and/or excipients.

REMARKS

For the sole reason of addressing non-substantive formalities issues, claims 1-14 have been cancelled without prejudice, and claims 15-23 have been added. No new matter has been